[go: up one dir, main page]

PE20020052A1 - Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato - Google Patents

Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato

Info

Publication number
PE20020052A1
PE20020052A1 PE2001000451A PE2001000451A PE20020052A1 PE 20020052 A1 PE20020052 A1 PE 20020052A1 PE 2001000451 A PE2001000451 A PE 2001000451A PE 2001000451 A PE2001000451 A PE 2001000451A PE 20020052 A1 PE20020052 A1 PE 20020052A1
Authority
PE
Peru
Prior art keywords
function
sulfonamid
enhance
glutamate receptor
derivatives useful
Prior art date
Application number
PE2001000451A
Other languages
English (en)
Inventor
Thomas John Bleisch
George William Cuff
Paul Leslie Ornstein
Dennis Michael Zimmerman
Macklin Brian Arnold
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20020052A1 publication Critical patent/PE20020052A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN COMPUESTO {(2R)-2-[4-(4-{2-[(METILSULFONIL)AMINO]ETIL}FENIL)FENIL]PROPIL}[(METILETIL)SULFONIL]AMINA DE FORMULA I EL CUAL POTENCIA LA FUNCION DE RECEPTORES DE GLUTAMATO Y PUEDE SER UTIL PARA TRATAR LA DEPRESION, ESQUIZOFRENIA
PE2001000451A 2000-05-19 2001-05-18 Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato PE20020052A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20600300P 2000-05-19 2000-05-19

Publications (1)

Publication Number Publication Date
PE20020052A1 true PE20020052A1 (es) 2002-02-02

Family

ID=22764580

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000451A PE20020052A1 (es) 2000-05-19 2001-05-18 Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato

Country Status (24)

Country Link
US (1) US20030225163A1 (es)
EP (1) EP1311474A1 (es)
JP (1) JP2003534316A (es)
KR (1) KR20030007644A (es)
CN (1) CN1429205A (es)
AR (1) AR035915A1 (es)
AU (1) AU2001259053A1 (es)
BR (1) BR0110874A (es)
CA (1) CA2409830A1 (es)
CZ (1) CZ20023797A3 (es)
DZ (1) DZ3343A1 (es)
EA (1) EA200201234A1 (es)
EC (1) ECSP014078A (es)
HR (1) HRP20020918A2 (es)
HU (1) HUP0302255A3 (es)
IL (1) IL152156A0 (es)
MX (1) MXPA02010020A (es)
NO (1) NO20025459D0 (es)
PE (1) PE20020052A1 (es)
PL (1) PL358180A1 (es)
SK (1) SK16312002A3 (es)
SV (1) SV2002000459A (es)
WO (1) WO2001090057A1 (es)
ZA (1) ZA200208749B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6984756B2 (en) 2000-05-19 2006-01-10 Eli Lilly And Company Process for preparing biphenyl compounds
ES2225558T3 (es) 2000-06-13 2005-03-16 Eli Lilly And Company Derivados de sulfonamida.
EP1438036A2 (en) * 2001-10-12 2004-07-21 Eli Lilly And Company Use of sulfonamide derivatives as pharmaceuticals compounds
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
EP2102153A1 (en) * 2006-12-11 2009-09-23 Eli Lilly & Company Ampa receptor potentiators
BR112015031249A2 (pt) 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525099B1 (en) * 1998-07-31 2003-02-25 Eli Lilly And Company N-substituted sulfonamide derivatives

Also Published As

Publication number Publication date
CA2409830A1 (en) 2001-11-29
EP1311474A1 (en) 2003-05-21
HUP0302255A2 (hu) 2003-11-28
SK16312002A3 (sk) 2003-05-02
NO20025459L (no) 2002-11-14
CN1429205A (zh) 2003-07-09
AR035915A1 (es) 2004-07-28
IL152156A0 (en) 2003-05-29
CZ20023797A3 (cs) 2003-04-16
NO20025459D0 (no) 2002-11-14
KR20030007644A (ko) 2003-01-23
ECSP014078A (es) 2002-02-25
BR0110874A (pt) 2003-02-11
JP2003534316A (ja) 2003-11-18
PL358180A1 (en) 2004-08-09
WO2001090057A1 (en) 2001-11-29
AU2001259053A1 (en) 2001-12-03
DZ3343A1 (fr) 2001-11-29
HRP20020918A2 (en) 2004-02-29
MXPA02010020A (es) 2003-02-12
ZA200208749B (en) 2004-01-30
US20030225163A1 (en) 2003-12-04
HUP0302255A3 (en) 2005-11-28
EA200201234A1 (ru) 2003-04-24
SV2002000459A (es) 2002-07-03

Similar Documents

Publication Publication Date Title
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
EA200702471A1 (ru) Новые гетероциклические соединения в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
ATE402945T1 (de) Neuer steroidagonist für fxr
PE20090641A1 (es) Amidas heterociclicas
EA200701121A1 (ru) Потенциаторы рецепторов глутамата
HRP20080226T3 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
IL187208A0 (en) Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
DK1685105T3 (da) Allosteriske modulatorer af metabotropiske glutamatreceptorer
NO20032253D0 (no) Piperazinylpyrazinforbindelser som antagonister av serotonin 5-HT2-reseptorer
CY1107954T1 (el) Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd
NO20071476L (no) Antidiuretiske midler.
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
DE602005025672D1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
PE20020052A1 (es) Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato
PE20090629A1 (es) Pirazinas y piperidinas piperazinil sustituidas como antagonistas del receptor 5-ht7
MXPA05008186A (es) Derivados de quinoxalina saturados y su uso como ligandos receptores de glutamato metabotropico.
MA28811B1 (fr) Nouvelles utilisations de derives d'imidazotriazinones substituees par 2-phenyle
EA200700364A1 (ru) Производные амида кинуреновой кислоты как антагонисты nr2b подтипа рецептора nmda
NO20081529L (no) Naftyridinderivater
UY26568A1 (es) Nuevos derivados de amidas heterocíclicas
PE20080279A1 (es) DERIVADOS DE PIRAZOL[4,3-d]TIAZOL COMO INHIBIDORES DE LA PROTEINA QUINASA AURORA 1 Y 2
DK1603877T3 (da) Nye aminopyridinderivater som mGIuR5 antagonister
HRP20080075T3 (hr) Fenil diazepan karboksamidi i anelirani fenil piperazin karboksamidi koji sadrže kisik kao antagonisti dopamina d3

Legal Events

Date Code Title Description
FC Refusal